NCT02712905 2025-11-04
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Loma Linda University
National Cancer Institute (NCI)